2026 Interim report
Filed with HKEX · Stock code 2185 · · 49 pages · English
2 Corporate Information 4 Financial Highlights 5 Management Discussion and Analysis 18 Other Information 26 Interim Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income 27 Interim Condensed Consolidated Statement of Financial Position 29 Interim Condensed Consolidated Statement of Changes in Equity 30 Interim Condensed Consolidated Statement of Cash Flows 32 Notes to t
Shanghai Bio-Heart Biological Technology Co., Ltd. on 6ix
Earlier from Shanghai Bio-Heart Biological Technology
- Proxy form for use at the 2026 first extraordinary general meeting to be held on October 9, 2026
- Proposed appointment of independent non-executive director; and (2) notice of 2026 first extraordinary general meeting
- Notice of 2026 first extraordinary general meeting
- Announcement pursuant to rule 13.51B(2) of the listing rules
- Voluntary announcement strategic cooperation agreement with shanghai shenqi medical technology co., ltd. to advance the commercialisation of the bioheart bioabsorbable rapamycin-eluting coronary stent system
Later from Shanghai Bio-Heart Biological Technology
- Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 September 2026
- (1) Poll results of the 2026 first extraordinary general meeting held on October 9, 2026; (2) resignation of independent non-executive director; (3) appointment of independent non-executive director; and (4) change of composition of board committees
- List of directors and their roles and functions
- Adoption of the china accounting standards for business enterprises for the preparation of financial reports on a uniform basis and proposed change of auditor
- Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 October 2026
Follow Shanghai Bio-Heart Biological Technology into a list and get an email when it puts out news.
Follow Shanghai Bio-Heart Biological Technology